US 12,290,652 B2
Treating tumors using TTFields combined with a PARP inhibitor
Michael Story, Austin, TX (US); Debabrata Saha, Carrollton, TX (US); and Narasimha Kumar Karanam, Dallas, TX (US)
Assigned to Novocure GmbH, Baar (CH)
Filed by Michael Story, Austin, TX (US); Debabrata Saha, Carrollton, TX (US); and Narasimha Kumar Karanam, Dallas, TX (US)
Filed on Feb. 11, 2021, as Appl. No. 17/173,694.
Application 17/173,694 is a continuation of application No. 15/938,088, filed on Mar. 28, 2018, granted, now 10,953,209.
Prior Publication US 2021/0268247 A1, Sep. 2, 2021
Int. Cl. A61M 37/00 (2006.01); A61K 31/502 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01)
CPC A61M 37/00 (2013.01) [A61K 31/502 (2013.01); A61N 5/10 (2013.01); A61P 35/00 (2018.01); A61M 2037/0007 (2013.01); A61M 2205/051 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of killing cancer cells selected from the group consisting of pancreatic cancer cells and ovarian cancer cells, comprising:
delivering a PARP inhibitor to the cancer cells; and
applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 80 and 300 kHz, wherein at least a portion of the applying step is performed simultaneously with at least a portion of the delivering step.